Seminars in Hematology
Volume 43, Issue 4 , Pages 240-250 , October 2006

Role of Hematopoietic Stem Cell Transplantation for Advanced-Stage Diffuse Large Cell B-Cell Lymphoma-B

  • Auayporn Nademanee

      Affiliations

    • Corresponding Author InformationAddress correspondence to Auayporn Nademanee, MD, Division of Hematology and Hematopoietic Cell Transplantation, 1500 E Duarte Rd, Duarte, CA 91010.
    • ,
  • Stephen J. Forman

References 

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous Bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545
  2. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol. 1997;15:1131–1137
  3. Weaver CH, Petersen FB, Appelbaum FA, Bensinger WI, Press O, Martin P, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol. 1994;12:2559–2566
  4. Horning SJ, Negrin RS, Chao NJ, Long GD, Hoppe RT, Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol. 1994;12:2552–2558
  5. Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant. 2003;9:529–539
  6. Gutierrez-Delgado F, Maloney DG, Press OW, Golden J, Holmberg LA, Maziarz RT, et al. Autologous stem cell transplantation for non-Hodgkin’s lymphoma: Comparison of radiation-based and chemotherapuy-only preparative regimens. Bone Marrow Transplant. 2001;28:455–461
  7. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:2208–2214
  8. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogeneous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527–2534
  9. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. Parma Group The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Blood. 1998;92:3562–3568
  10. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16:3264–3269
  11. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102:1989–1996
  12. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102:53–59
  13. Alousi AM, Saliba RM, Okoroji G, Hosing C, Samuels BI, Champlin RE, et al. The influence of PET/gallium (P/G) status and high-dose rituximab (HDR) in patients (pts) with aggressive, large, B-cell lymphoma (LBCL) receiving autologous stem cell transplants (ASCT). J Clin Oncol (Meeting Abstracts). 2006;24:6518;(abstr)
  14. Cortelazzo S, Rambaldi A, Rossi A, Oldani E, Ghielmini M, Benedetti F, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin’s lymphoma. Br J Haematol. 2001;114:333–341
  15. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin’s lymphoma: Results of a multicenter phase II study. Ann Oncol. 2005;16:1359–1365
  16. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  17. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391
  18. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688
  19. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2005;23:2240–2247
  20. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103:777–783
  21. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, et al. Autotransplantation for advanced lymphoma and Hodgkin’s disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant. 2002;29:303–312
  22. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219–1224
  23. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942
  24. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896–2902
  25. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:461–467
  26. Winter JN, Inwards D, Erwin W, Wiseman G, Rademaker A, Patton DR, et al. Zevalin dose-escalation foolowed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin’s lymphoma: Early outcome results. Blood. 2002;100:411a;(abstr)
  27. Krishnan AY, Nademanee A, Forman SJ, Fung H, Molina A, Yamauchi D, et al. The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin’s lymphoma (NHL). J Clin Oncol (Meeting Abstracts). 2005;23:6566;(abstr)
  28. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: Results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:2796–2802
  29. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–1295
  30. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472–2479
  31. Kaiser U, Uebelacker L, Abel U, Birkmann J, Trümper L, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol. 2002;20:4413–4419
  32. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, de Vivo A, Cantonetti M, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: An Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255–1262
  33. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst. 2001;93:22–30
  34. Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma in adults 60 years of age and older. Bone Marrow Transplant. 2001;27:593–599
  35. Jantunen E, Itala M, Juvonen E, Leppa S, Keskinen L, Vasala K, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin’s lymphoma: A nation-wide analysis. Bone Marrow Transplant. 2006;37:367–372
  36. Peniket AJ, De Elvira MCR, Taghipour G, Cordonnier C, Gluckman E, De Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–678
  37. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry. Blood. 2004;104:3797–3803
  38. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310–4316
  39. Rodriguez R, Nademanee A, Carter N, Smith E, Krishnan A, Popplewell L, et al: Comparison of reduced intensity with conventional myeloablative regimens for allogeneic transplant of non-Hodgkin lymphoma. (submitted for publication)
  40. Mackinnon S. Reduced intensity allogeneic stem cell transplantation for relapsed Hodgkin and non-Hodgkin’s lymphoma lowers regimen toxicity and facilitates a graft-versus-lymphoma effect. Ann Oncol. 2005;16:v34;(abstr)
  41. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3776–3785
  42. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–122
  43. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP—An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4 year follow-up study. J Clin Oncol. 1994;12:1169–1176
  44. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987;5:407–412
  45. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287–299
  46. O’Connor OA, Heaney ML, Schwartz L, Richardson S, William R, MacGregor-Cortelli B, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166–173
  47. Moskowitz CH. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation. Ann Oncol. 2006;17:iv37–iv39
  48. Gillies SD, Lan Y, Williams S, Carr F, Forman S, Raubitschek A, et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood. 2005;105:3972–3978
  49. Cooper LJ, Kalos M, DiGiusto D, Brown C, Forman SJ, Raubitschek A, et al. T-cell genetic modification for re-directed tumor recognition. Cancer Chemother Biol Response Modif. 2005;22:293–324
  50. Jensen M. Strategies to enhance the therapeutic efficacy of autologous hematopoietic stem cell transplantation by posttransplantation adoptive transfer of T cells with engineered graft-versus-tumor activity. Biol Blood Marrow Transplant. 2005;11:34–39
  51. Gianni AM, Bregni M, Siena S, Brambilla C, Nicola MD, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290–1297
  52. Olivieri A, Santini G, Patti C, Chisesi T, De Souza C, Rubagotti A, et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin’s lymphoma: Long-term results by the NHLCSG. Ann Oncol. 2005;16:1941–1948

 Supported in part by United States Public Health Service Grants No. CA30206 and CA33572.

PII: S0037-1963(06)00154-5

doi: 10.1053/j.seminhematol.2006.07.006

Seminars in Hematology
Volume 43, Issue 4 , Pages 240-250 , October 2006

Article Tools

* Image Usage & Resolution